Furthermore, we observed that patients in the two clusters exhibited significantly different clinicopathological features, including molecular subtypes, tumor grade, T stage, N stage, P53 mutation, and the expression of Ki-67, HER2, PR, and ER (Figure 2D; Table 1). This evidence concerns the gene TP53 and neoplasm.